Synthetic Biologics, Inc.(NYSE Amex Equities : SYN)
(
)
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | -4.95% | 408.84 | 0.0% | $5581.83m | |
| BNTX | BioNTech SE | -7.91% | 307.09 | 0.0% | $959.22m | |
| NVAX | Novavax, Inc. | -6.90% | 231.04 | 79.4% | $918.58m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | -3.24% | 8.37 | 0.7% | $585.09m | |
| AMGN | Amgen, Inc. | -0.23% | 213.11 | 1.4% | $539.22m | |
| GILD | Gilead Sciences, Inc. | -1.10% | 70.41 | 1.0% | $450.06m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -3.10% | 619.07 | 2.7% | $422.20m | |
| ILMN | Illumina, Inc. | -1.67% | 425.58 | 3.5% | $353.17m | |
| BIIB | Biogen, Inc. | -1.75% | 286.62 | 1.7% | $310.33m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -0.11% | 183.41 | 1.9% | $248.50m | |
| ISEE | IVERIC bio, Inc. | 6.90% | 17.50 | 0.0% | $218.29m | |
| LIFE | aTyr Pharma, Inc. | -3.42% | 9.90 | 2.1% | $159.03m | |
| BGNE | BeiGene Ltd. | -0.62% | 377.18 | 1.3% | $147.82m | |
| TECH | Bio-Techne Corp. | -5.09% | 511.45 | 4.5% | $138.52m | |
| KDMN | Kadmon Holdings, Inc. | 0.11% | 8.84 | 0.8% | $135.49m |
Company Profile
Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.